Home > Signaling Pathways>Transmembrane>TRP Channel>A-967079
A-967079

This product is for research use only, not for human use. We do not sell to patients.

A-967079
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$500Check With Us
250mg$950Check With Us
500mg$1375Check With Us
email: [email protected]        [email protected]

Cat #: V6545 CAS #: 1170613-55-4 Purity ≥ 99%

Description: A-967079 is a novel, potent, CNS-penetrant and selective blocker/antagonist TRPA1 channel (IC50s of 67 nM and 289 nM at human and rat TRPA1 receptors), with analgesic and antiinflammatory effects and is used in scientific research, but has not been developed for medical use.

References: McGaraughty S, et al. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured, osteoarthritic, and inflamed rats. Mol Pain. 2010 Mar 5; 6:14.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)207.2484
Molecular FormulaC12H14FNO
CAS No.1170613-55-4
SynonymsA-967079; A967079; A 967079
ProtocolIn VivoSystemic injection of A-967079 (30 μmol/kg, intravenously) reduced the response of wide dynamic range (WDR) and nociceptive specificity (NS) neurons after nociceptive pinching stimulation in ipsilateral hindpaw in uninjured and Freund's adjuvant (CFA)-inflamed rats. Similar to its effect in uninjured rats, in CFA-inflamed rats, administration of A-967079 (30 μmol/kg, intravenously) significantly reduced WDR neuronal response to noxious pinching stimuli compared with baseline discharge (p=0.0013, replicate-measure ANOVA) compared with baseline discharge and control (p=0.0001, two-way ANOVA). The maximum observed effect on pinching-induced activity in inflamed rats occurred 35 min after injection (61.1±10.97% lower than baseline level). Injection of A-967079 into rats with CFA inflammation also significantly (p=0.0004 and p=0.0001 for repeated measures and two-way ANOVA, respectively) reduced WDR neuronal response to 10-g von Frey hair stimulation compared to uninjured rats. The largest reduction observed in von Frey-evoked activity was 35.67±69.18% of the baseline level (39 min post-injection) and was therefore comparable to the effect of A-967079 on pinch-evoked activity in inflamed rats
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM4.8251 mL24.1256 mL48.2513 mL96.5026 mL
5mM0.9650 mL4.8251 mL9.6503 mL19.3005 mL
10mM0.4825 mL2.4126 mL4.8251 mL9.6503 mL
20mM0.2413 mL1.2063 mL2.4126 mL4.8251 mL
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.